Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- semaglutide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Anniston,Birmingham,Fountain Hills,Glendale,Mesa,Phoenix,Tucson,Tucson,Anaheim,Fresno,Los Angeles,Los Angeles,Riverside,Van Nuys,Vista,Colorado Springs,Denver,Hialeah,Atlanta,Chicago,Franklin,Lexingto, Canada,France,Greece,India,Japan,Mexico,Poland,Puerto Rico,Russian Federation,United States of Ameri
- Phase
- Phase 3
- Start date
- Feb 02, 2017
- End date
- Aug 22, 2018
- Enrollment
- 731 participants
Change in HbA1c (Week 26)
This trial is conducted globally. The aim of the trial is to investigate the efficacy and
 safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated
 with insulin. All subjects should continue their pre-trial insulin therapy (basal,
 basal-bolus or premixed regimen including combinations of soluble insulins) throughout the
 trial. Subjects treated with metformin in addition to insulin treatment must continue their
 metformin treatment throughout the entire trial.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03021187
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03021187 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 731 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.